Cargando…

Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report

BACKGROUND: Patients undergone kidney transplantation present higher risk of Urothelial Carcinoma (UC) development and represent a subgroup of special interest. To date, vinflunine is the only drug approved in Europe for the treatment of advanced UC after failure of platinum-based chemotherapy. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bordi, Paola, Tiseo, Marcello, Baldari, Giorgio, Buti, Sebastiano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4983020/ https://www.ncbi.nlm.nih.gov/pubmed/27519420 http://dx.doi.org/10.1186/s12885-016-2666-6

Ejemplares similares

Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer
por: Bernardini, Alejandra, et al.
Publicado: (2022)

Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)(†)
por: De Santis, M., et al.
Publicado: (2016)

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
por: Facchinetti, Francesco, et al.
Publicado: (2018)

Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma
por: Morel, Armand, et al.
Publicado: (2010)

Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma
por: Font, Albert, et al.
Publicado: (2021)

From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples
por: Facchini, Gaetano, et al.
Publicado: (2016)

The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine
por: Harshman, L C, et al.
Publicado: (2013)

Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis
por: Holmsten, Karin, et al.
Publicado: (2016)

Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis
por: Holmsten, Karin, et al.
Publicado: (2017)

Monoinstitutional real world experience in management of Vinflunine as second line therapy for transitional cell carcinoma of the urothelium
por: Schinzari, Giovanni, et al.
Publicado: (2018)

Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study
por: Médioni, Jacques, et al.
Publicado: (2016)

VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland
por: Hussain, Syed A., et al.
Publicado: (2017)

Vinflunine in the treatment of bladder cancer
por: Bachner, Mark, et al.
Publicado: (2008)

Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience
por: Retz, Margitta, et al.
Publicado: (2015)

Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy
por: Brousell, Steven C, et al.
Publicado: (2018)

Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group
por: Pistamaltzian, Nikolaos, et al.
Publicado: (2016)

Safety and Activity of Sorafenib in Addition to Vinflunine in Post‐Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial
por: Shah, Carl‐Henrik, et al.
Publicado: (2018)

Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model
por: Holwell, S E, et al.
Publicado: (2001)

Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatment—A Retrospective Multicenter Analysis
por: Riedel, Felix, et al.
Publicado: (2022)

Stathmin Potentiates Vinflunine and Inhibits Paclitaxel Activity
por: Malesinski, Soazig, et al.
Publicado: (2015)

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
por: Fradet, Y, et al.
Publicado: (2019)

Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy
por: Campone, M, et al.
Publicado: (2006)

Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
por: Verzè, Michela, et al.
Publicado: (2021)

Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice
por: Castellano, Daniel, et al.
Publicado: (2014)

Comparative study of the radiosensitising and cell cycle effects of vinflunine and vinorelbine, in vitro
por: Simoens, Cindy, et al.
Publicado: (2008)

Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01–2014)
por: Passalacqua, Rodolfo, et al.
Publicado: (2017)

Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts
por: Santini, Daniele, et al.
Publicado: (2023)

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen
por: Culine, S, et al.
Publicado: (2006)

VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis
por: Nicholson, Steve, et al.
Publicado: (2021)

Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor
por: Chiang, Ryan S., et al.
Publicado: (2020)

Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy
por: Bersanelli, Melissa, et al.
Publicado: (2020)

New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
por: Bamias, Aristotelis, et al.
Publicado: (2023)

Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development
por: Kruczynski, A, et al.
Publicado: (2002)

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors
por: Dall’Olio, Filippo G., et al.
Publicado: (2020)

Role of the microtubule-targeting drug vinflunine on cell-cell adhesions in bladder epithelial tumour cells
por: Aparicio, Luis A, et al.
Publicado: (2014)

Urothelial carcinoma of donor origin in a kidney transplant patient
por: Michel Ortega, Rosa M., et al.
Publicado: (2016)

Incidences and oncological outcomes of urothelial carcinoma in kidney transplant recipients
por: Yu, Jiwoong, et al.
Publicado: (2018)

Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma
por: Suekane, Shigetaka, et al.
Publicado: (2017)

Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics()()
por: Vallo, Stefan, et al.
Publicado: (2015)

Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study
por: Bersanelli, Melissa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s9qs8jd561ajp6u27gjas784ni